Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced that it has initiated an international Phase 2 clinical trial with sovaprevir and ACH-3102 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE